Dec 7, 2020. https://ash.confex.com/ash/2020/webprogram/Paper139526.html
I don't know if you have seen this yet, @RaceOncology, but FTO overexpression was found and linked with poor prognosis in chronic lymphocytic leukemia (CLL) and silencing or pharmacological inhibition of FTO resulted in reduced proliferation and increased apoptosis in CLL cells. As we know, the IC-50 value of FB23-2 is much larger than bisantrenes, indicating that bisantrene could be a more effective inhibitor in this model.
Looks like another to add to the chart below.
Pillar 1 - FTO (new thread), page-423
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
-0.020(1.25%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.59 | $293.1K | 180.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8233 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 400 | 1 |
View Market Depth
| Last trade - 11.02am 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |